Amphastar Pharmaceuticals (NASDAQ: AMPH) Q1 2026 EPS Misses by Wide Margin, Stock Drops

Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) delivered a first-quarter 2026 adjusted EPS of $0.42, falling well short of the $0.72 consensus estimate and sending shares down roughly 10% in after-hours trading. Net revenues of $171.2 million were essentially flat year-over-year, offering little to offset the profit disappointment. The company confirmed results via an SEC EDGAR 8-K filing dated May 7, 2026.

Q1 2026 At a Glance

• Net revenues: $171.2 million for the three months ended March 31, 2026
• GAAP net income: $6.4 million, or $0.14 per share
• Adjusted non-GAAP net income: $19.5 million, or $0.42 per share
• Adjusted EPS vs. estimate: $0.42 actual vs. $0.72 expected — a significant shortfall
• Gross margin: 49.5% | Operating margin: 19.4% | Net margin: 13.6%
• Revenue growth (YoY): -1.8% | Net income growth (YoY): -31.0%
• Market cap: $1.1 billion | Trailing P/E: 11.8x | Forward P/E: 6.9x

What Drove the Results

The gap between GAAP net income of $6.4 million and adjusted non-GAAP net income of $19.5 million signals meaningful non-cash or one-time charges weighing on reported profitability in the quarter. A year-over-year decline in net income of 31.0% alongside nearly flat revenues of $171.2 million points to margin compression rather than a top-line collapse — the company's 49.5% gross margin remains respectable for a specialty pharmaceutical manufacturer, but rising costs appear to have pressured the bottom line.

The revenue growth rate of -1.8% year-over-year reflects a broadly stable but not expanding business at this stage. With a forward P/E of just 6.9x against a trailing P/E of 11.8x, the market appears to be pricing in a meaningful recovery in per-share profitability over the next twelve months — a narrative that will need execution to validate.

Wall Street View

Despite the earnings miss, analyst sentiment remains broadly constructive. As of May 1, 2026, the consensus stood at 2 Strong Buy, 5 Buy, and 6 Hold, with zero Sell or Strong Sell ratings. Comparing to the prior month's distribution of 3 Strong Buy, 5 Buy, and 5 Hold, there is a modest softening — one Strong Buy shifted to Hold — suggesting some caution crept in around the print, though the overall tone remains positive.

Investor Takeaway

The Q1 2026 results represent a clear near-term setback for Amphastar Pharmaceuticals (NASDAQ: AMPH), with adjusted EPS missing by $0.30 per share and year-over-year net income declining 31.0%. That said, the majority of covering analysts maintain a Buy-leaning stance, and the 6.9x forward P/E implies the market is not dismissing a recovery path entirely. Investors will likely monitor whether the company can rebuild profitability in coming quarters, particularly given management's upcoming presentation at the 2026 Bank of America Health Care Conference.